about research careers contact
About Hua Medicine
Hua Medicine is a leading clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action. Hua has successfully brought this compound into Phase 1 clinical trials in China with the goal of initiating Phase 2 trials by 3Q2014.

The company has also internally developed two earlier-stage compounds focused on a clinically-validated CNS target spanning multiple indications, including potential treatments for specific neurodegenerative disorders. Hua retains world-wide rights to both its in-licensed and internally developed products.

5.21 2014

3.26 2014
Hua Medicine tests glucokinase activator in Chinese diabetics

3.20 2014
Hua Medicine Reports Strong Results for Early Diabetes Drug Trial

4.1 2014

3.19 2014
Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients

3.19 2014

2.28 2014
忆张江 - 机会在中国

1.2 2014
Hua exploits in-licensing opportunities, focuses on unmet needs in China

12.1 2013

9.6 2013
华领医药抗糖尿病创新药进入临床 I 期研究

9.6 2013
Hua Medicine T2D Drug Entered into Clinical Trial in China

9.6 2013
Hua Medicine Begins Phase I Trial of Novel Diabetes Treatment

4.24 2013
2012年度浦东“百人计划”揭晓 12名高层次人才入选

1.9 2013

11.23 2012
Hua Medicine Advances Diabetes Treatment toward Trial

11.19 2012
China’s Green Channel Significantly Shortened Filing Time For Start-up Hua Medicine

6.19 2012
Biotech is a fast growing sector in China – both for manufacturing and R&D.

5.23 2012

  • part1
  • part2
  • part3